These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

771 related articles for article (PubMed ID: 28359566)

  • 21. Cerebrospinal fluid cortisol and clinical disease progression in MCI and dementia of Alzheimer's type.
    Popp J; Wolfsgruber S; Heuser I; Peters O; Hüll M; Schröder J; Möller HJ; Lewczuk P; Schneider A; Jahn H; Luckhaus C; Perneczky R; Frölich L; Wagner M; Maier W; Wiltfang J; Kornhuber J; Jessen F
    Neurobiol Aging; 2015 Feb; 36(2):601-7. PubMed ID: 25435336
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cerebrospinal fluid BACE1 activity and markers of amyloid precursor protein metabolism and axonal degeneration in Alzheimer's disease.
    Perneczky R; Alexopoulos P;
    Alzheimers Dement; 2014 Oct; 10(5 Suppl):S425-S429.e1. PubMed ID: 24239250
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A Novel Plasma Based Biomarker of Alzheimer's Disease.
    Bradley-Whitman MA; Abner E; Lynn BC; Lovell MA
    J Alzheimers Dis; 2015; 47(3):761-71. PubMed ID: 26401710
    [TBL] [Abstract][Full Text] [Related]  

  • 24. High activities of BACE1 in brains with mild cognitive impairment.
    Cheng X; He P; Lee T; Yao H; Li R; Shen Y
    Am J Pathol; 2014 Jan; 184(1):141-7. PubMed ID: 24332014
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Alterations in the Expression of Amyloid Precursor Protein Cleaving Enzymes mRNA in Alzheimer Peripheral Blood.
    Wongchitrat P; Pakpian N; Kitidee K; Phopin K; Dharmasaroja PA; Govitrapong P
    Curr Alzheimer Res; 2019; 16(1):29-38. PubMed ID: 30411686
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The relationship of plasma Aβ levels to dementia in aging individuals with mild cognitive impairment.
    Fei M; Jianghua W; Rujuan M; Wei Z; Qian W
    J Neurol Sci; 2011 Jun; 305(1-2):92-6. PubMed ID: 21440911
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Characterization of Cerebrospinal Fluid BACE1 Species.
    Lopez-Font I; Boix CP; Zetterberg H; Blennow K; Sáez-Valero J
    Mol Neurobiol; 2019 Dec; 56(12):8603-8616. PubMed ID: 31290061
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Platelet-derived secreted amyloid-precursor protein-β as a marker for diagnosing Alzheimer's disease.
    Marksteiner J; Humpel C
    Curr Neurovasc Res; 2013 Nov; 10(4):297-303. PubMed ID: 23937201
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Combining Cerebrospinal Fluid Biomarkers and Neuropsychological Assessment: A Simple and Cost-Effective Algorithm to Predict the Progression from Mild Cognitive Impairment to Alzheimer's Disease Dementia.
    Mazzeo S; Santangelo R; Bernasconi MP; Cecchetti G; Fiorino A; Pinto P; Passerini G; Falautano M; Comi G; Magnani G
    J Alzheimers Dis; 2016 Oct; 54(4):1495-1508. PubMed ID: 27589522
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Associations of Plasma BACE1 Level and BACE1 C786G Gene Polymorphism with Cognitive Functions in Patients with Type 2 Diabetes: A Cross- Sectional Study.
    Tian S; Huang R; Guo D; Lin H; Wang J; An K; Wang S
    Curr Alzheimer Res; 2020; 17(4):355-364. PubMed ID: 32442083
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Increased plasma TACE activity in subjects with mild cognitive impairment and patients with Alzheimer's disease.
    Sun Q; Hampel H; Blennow K; Lista S; Levey A; Tang B; Li R; Shen Y
    J Alzheimers Dis; 2014; 41(3):877-86. PubMed ID: 24685635
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Beta-site amyloid precursor protein cleaving enzyme 1 (BACE1) as a biological candidate marker of Alzheimer's disease.
    Hampel H; Shen Y
    Scand J Clin Lab Invest; 2009; 69(1):8-12. PubMed ID: 18609117
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cerebrospinal fluid levels of β-amyloid 1-42, but not of tau, are fully changed already 5 to 10 years before the onset of Alzheimer dementia.
    Buchhave P; Minthon L; Zetterberg H; Wallin AK; Blennow K; Hansson O
    Arch Gen Psychiatry; 2012 Jan; 69(1):98-106. PubMed ID: 22213792
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Impact of Depressive Symptoms on Conversion from Mild Cognitive Impairment Subtypes to Alzheimer's Disease: A Community-Based Longitudinal Study.
    Kida J; Nemoto K; Ikejima C; Bun S; Kakuma T; Mizukami K; Asada T
    J Alzheimers Dis; 2016; 51(2):405-15. PubMed ID: 26890740
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Amyloid-β misfolding as a plasma biomarker indicates risk for future clinical Alzheimer's disease in individuals with subjective cognitive decline.
    Stockmann J; Verberk IMW; Timmesfeld N; Denz R; Budde B; Lange-Leifhelm J; Scheltens P; van der Flier WM; Nabers A; Teunissen CE; Gerwert K
    Alzheimers Res Ther; 2020 Dec; 12(1):169. PubMed ID: 33357241
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Neuropsychological Contribution to Predict Conversion to Dementia in Patients with Mild Cognitive Impairment Due to Alzheimer's Disease.
    Silva D; Cardoso S; Guerreiro M; Maroco J; Mendes T; Alves L; Nogueira J; Baldeiras I; Santana I; de Mendonça A
    J Alzheimers Dis; 2020; 74(3):785-796. PubMed ID: 32083585
    [TBL] [Abstract][Full Text] [Related]  

  • 37. BACE1 activity in cerebrospinal fluid and its relation to markers of AD pathology.
    Mulder SD; van der Flier WM; Verheijen JH; Mulder C; Scheltens P; Blankenstein MA; Hack CE; Veerhuis R
    J Alzheimers Dis; 2010; 20(1):253-60. PubMed ID: 20164582
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [The new 2011 recommendations of the National Institute on Aging and the Alzheimer's Association on diagnostic guidelines for Alzheimer's disease: Preclinal stages, mild cognitive impairment, and dementia].
    Croisile B; Auriacombe S; Etcharry-Bouyx F; Vercelletto M; ;
    Rev Neurol (Paris); 2012 Jun; 168(6-7):471-82. PubMed ID: 22579080
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Accuracy of verbal fluency tests in the discrimination of mild cognitive impairment and probable Alzheimer's disease in older Spanish monolingual individuals.
    García-Herranz S; Díaz-Mardomingo MC; Venero C; Peraita H
    Neuropsychol Dev Cogn B Aging Neuropsychol Cogn; 2020 Nov; 27(6):826-840. PubMed ID: 31822214
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Diagnostic and Prognostic Value of the Combination of Two Measures of Verbal Memory in Mild Cognitive Impairment due to Alzheimer's Disease.
    Sala I; Illán-Gala I; Alcolea D; Sánchez-Saudinós MB; Salgado SA; Morenas-Rodríguez E; Subirana A; Videla L; Clarimón J; Carmona-Iragui M; Ribosa-Nogué R; Blesa R; Fortea J; Lleó A
    J Alzheimers Dis; 2017; 58(3):909-918. PubMed ID: 28527215
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 39.